Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206583 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of an Oral Contraceptive in Healthy Females
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 499
- Enrollment target
NCT00206583 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 499 participants.
The verdict
NCT00206583, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 499 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the study drug is safe and effective in the prevention of pregnancies in a large group of volunteers.
Interventions
- DRUG EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 499 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206583
The ClinicalTrials.gov registry entry for NCT00206583 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 499 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EV/DNG (Qlaira, BAY86-5027, SH T00658ID) is the first listed.
NCT00206583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206583 about?
NCT00206583 is a clinical study titled "Efficacy and Safety Study of an Oral Contraceptive in Healthy Females". The purpose of this study is to determine whether the study drug is safe and effective in the prevention of pregnancies in a large group of volunteers.
What is the current status of trial NCT00206583?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 499 participants. The study started on 2005-03. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00206583?
The interventions under investigation include: EV/DNG (Qlaira, BAY86-5027, SH T00658ID) (DRUG).
Who is sponsoring clinical trial NCT00206583?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.